Clinical Trial Update: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating IL-15-Armored CAR-T therapy in relapsed or refractory multiple myeloma and plasma cell leukemia; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• IL-15-Armored CAR-T Therapy

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL) | Phase 2 | Status: RECRUITING